As a key platform for sharing global innovative achievements, the China International Import Expo (CIIE) continues to accelerate the access of high-quality medical products to the Chinese market, fostering multi-stakeholder cooperation and mutual benefit. During the 8th CIIE, Gilead Sciences, a world-leading biopharmaceutical company, signed multiple strategic cooperation agreements. It actively partners with various stakeholders to build a "patient-centric" medical service ecosystem focusing on improving drug accessibility, promoting standardized diagnosis and treatment, and deepening the integration of medical treatment and prevention, so as to jointly create a healthy and promising future.
Jin Fangqian, Vice President of Gilead Sciences Global and General Manager of Gilead China, stated: "Since entering China more than eight years ago, Gilead has always been patient-centric, striving to bring global innovative therapies to Chinese patients quickly. To date, the 13 innovative drugs officially approved in China have benefited approximately 1.8 million patients cumulatively. Leveraging the open platform of CIIE, we continue to expand our cooperation network, promote greater access to innovative drugs, and enhance patients' treatment experience and quality of life. Looking ahead, Gilead will continue to walk side by side with all parties to make continuous contributions to improving the health of the Chinese public."
